Text Size

An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) as Maintenance Treatment in Patients With Chronic Renal Anemia on Haemodialysis

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Hoffmann-La Roche
ClinicalTrials.gov Identifier:
NCT01422824
First received: August 23, 2011
Last updated: May 7, 2013
Last verified: May 2013
History of Changes
  Purpose

This prospective observational study will evaluate the safety and efficacy of Mircera (methoxy polyethylene glycol-epoetin beta) in patients with chronic renal anemia on haemodialysis in maintenance ESA treatment. Data will be collected from patients receiving once monthly Mircera according to standard of care and local labelling during 12 months of treatment.


Condition
Anemia, Kidney Disease, Chronic

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An Observational. Non-interventional Study to Observe the Safety and Efficacy of MIRCERA in the Treatment of Chronic Renal Anemia in Maintenance ESA Treated Patients on Haemodialysis (STABILE)

Resource links provided by NLM:

MedlinePlus related topics: Anemia Dialysis
U.S. FDA Resources

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Safety: Incidence of adverse events [ Time Frame: approximately 2.5 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Long-term maintenance of hemoglobin levels [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Enrollment: 185
Study Start Date: June 2010
Estimated Study Completion Date: May 2014
Estimated Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients with chronic renal anemia on haemodialysis in maintenance ESA treatment

Criteria

Inclusion Criteria:

  • Adult patients, >/= 18 years of age
  • Stage IV chronic kidney disease, on haemodialysis
  • Chronic renal anemia, on maintenance ESA treatment
  • Hemoglobin concentration between 10.0 an 12 g/dL
  • Continuous maintenance epoetin therapy with the same dosing interval during the previous month

Exclusion Criteria:

  • Contraindications to ESA treatment (e.g. hypersensitivity, non-controlled hypertension)
  • Hemoglobinopathies (e.g. homozygous sickle-cell disease, thalassemia of all types)
  • Anemia due to hemolysis, pure red cell aplasia
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01422824

Locations
Macedonia, The Former Yugoslav Republic of
Delcevo, Macedonia, The Former Yugoslav Republic of, 2320
Prilep, Macedonia, The Former Yugoslav Republic of, 7500
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
Stip, Macedonia, The Former Yugoslav Republic of, 2000
Struga, Macedonia, The Former Yugoslav Republic of, 6000
Strumica, Macedonia, The Former Yugoslav Republic of, 2400
Sponsors and Collaborators
Hoffmann-La Roche
Investigators
Study Director: Clinical Trials Hoffmann-La Roche
  More Information

No publications provided

Responsible Party: Hoffmann-La Roche
ClinicalTrials.gov Identifier: NCT01422824     History of Changes
Other Study ID Numbers: ML25067
Study First Received: August 23, 2011
Last Updated: May 7, 2013
Health Authority: Macedonia: Ministry of Health

Additional relevant MeSH terms:
Anemia
Chronic Disease
Kidney Diseases
Renal Insufficiency, Chronic
Kidney Failure, Chronic
 Hematologic Diseases
Disease Attributes
Pathologic Processes
Urologic Diseases
Renal Insufficiency

ClinicalTrials.gov processed this record on May 16, 2013